Location
Cherry Auditorium, Kirk Hall
Start Date
11-10-2016 1:00 PM
Description
We target vascularization as a critical enabling technology to engineer or regenerate virtually any tissue or organ system. One important target for new therapies is peripheral artery disease (PAD). Current therapies for PAD aim to reduce risk with lifestyle changes, antiplatelet drugs, and statins before intervening surgically with either bypass or endovascular revascularization. However, for those patients who fail to respond to first-line therapies, the manifestations of PAD include critical limb ischemia (CLI). Staggeringly, ~25% of CLI patients will likely die within a year of the initial treatment. Despite positive results with animal studies and small-scale clinical studies, large clinical trials of protein-based and stem cell-based approaches for CLI, have not demonstrated a significant effect. Why has there been such poor correlation between animal studies and clinical trials to date? There are multiple potential reasons involving both engineering and biological aspects. We expect to discuss some of these challenges during this talk.
Speaker Bio
Eduardo A. Silva received his degree in Metallurgical and Materials Science Engineering from University of Porto, Portugal, in 2001. That same year, he was awarded a scholarship through the Gulbenkian foundation to do his PhD in Biomedicine, being the first engineer to be awarded this scholarship. He received his PhD in Engineering Sciences: Bioengineering in 2008 while working in the laboratory of Prof. David Mooney (Harvard University). After the completion of his PhD, Eduardo was awarded with a Wyss Technology Development fellowship. The Wyss Institute for Biologically Inspired Engineering (Harvard University) selected fellows on the basis of their academic achievements and their technology development potential in the field of Biologically Inspired Engineering. In Nov. 2011, Eduardo was appointed as Assistant Professor at the Department of Biomedical Engineering at the University of California, Davis. His laboratory aims to develop new material-based strategies intended to minimize any manipulations of biological agents outside the body. His research group motto is to drive and dictate in situ regenerative medicine with polymeric systems.
Polymer systems for controlled release of lentivectors
Cherry Auditorium, Kirk Hall
We target vascularization as a critical enabling technology to engineer or regenerate virtually any tissue or organ system. One important target for new therapies is peripheral artery disease (PAD). Current therapies for PAD aim to reduce risk with lifestyle changes, antiplatelet drugs, and statins before intervening surgically with either bypass or endovascular revascularization. However, for those patients who fail to respond to first-line therapies, the manifestations of PAD include critical limb ischemia (CLI). Staggeringly, ~25% of CLI patients will likely die within a year of the initial treatment. Despite positive results with animal studies and small-scale clinical studies, large clinical trials of protein-based and stem cell-based approaches for CLI, have not demonstrated a significant effect. Why has there been such poor correlation between animal studies and clinical trials to date? There are multiple potential reasons involving both engineering and biological aspects. We expect to discuss some of these challenges during this talk.
Comments
Downloadable file is a PDF of the original event flier.